Ads
related to: best areds for macular degeneration
Search results
Results from the WOW.Com Content Network
The incidence of age-related macular degeneration and its associated features increases with age and is low in people <55 years of age. [101] Smoking is the strongest modifiable risk factor. [102] As of 2008, age-related macular degeneration accounts for more than 54% of all vision loss in the white population in the US. [103]
The Age-Related Eye Disease Study (AREDS) was a clinical trial sponsored by the National Eye Institute that ran from 1992 to 2001. [1] The study was designed to: investigate the natural history and risk factors of age-related macular degeneration (AMD) and cataracts, and
Vitelliform macular dystrophy is an irregular autosomal dominant eye disorder which can cause progressive vision loss. [1] This disorder affects the retina , specifically cells in a small area near the center of the retina called the macula .
Comparison of Age-Related Macular Degeneration Treatments Trial: Lucentis-Avastin Trial: This two-year, multicenter clinical trial compared the effectiveness of two treatments used for AMD: Lucentis and Avastin. It showed that both treatments are equally effective in treating AMD and improving vision, whether used monthly or as needed.
Age-related macular degeneration (AMD) is a disease that affects the eyes and can lead to vision loss through break down of the central part of the retina called the macula. Degeneration can occur in one eye or both and can be classified as either wet (neovascular) or dry (atrophic).
Drusen associated with aging and macular degeneration are distinct from another clinical entity, optic disc drusen, which is present on the optic nerve head. [2] Both age-related drusen and optic disc drusen can be observed by ophthalmoscopy.
Ads
related to: best areds for macular degeneration